Literature DB >> 7030086

Prostaglandin control of plasma and platelet 5-hydroxytryptamine in normal and embolized animals.

T Utsunomiya, M M Krausz, D Shepro, H B Hechtman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030086     DOI: 10.1152/ajpheart.1981.241.5.H766

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


× No keyword cloud information.
  7 in total

1.  Increase in exhaled nitric oxide and protective role of the nitric oxide system in experimental pulmonary embolism.

Authors:  K F Nilsson; L E Gustafsson; L C Adding; D Linnarsson; P Agvald
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

2.  Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism.

Authors:  W V Huval; M A Mathieson; L I Stemp; B M Dunham; A G Jones; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

3.  Thromboxane mediation of cardiopulmonary effects of embolism.

Authors:  T Utsonomiya; M M Krausz; L Levine; D Shepro; H B Hechtman
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

Review 4.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

5.  Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.

Authors: 
Journal:  BMJ       Date:  1989-02-18

6.  The flavonoid luteolin inhibits niacin-induced flush.

Authors:  D Papaliodis; W Boucher; D Kempuraj; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

7.  Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.

Authors:  M D McGoon; P M Vanhoutte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.